Periodic Reporting for period 1 - NEW-AGE (A next-generation platform for catalysing pre-clinical development of drugs against Alzheimer’s and other degenerative diseases of old-age)
Okres sprawozdawczy: 2017-02-01 do 2018-07-31
Our solution to this problem is relevant to a broad range of degenerative conditions and the aging process itself. It exploits the fact that, whilst degenerative diseases are complex and multifactorial, they share a fundamental and universal feature in that their pathogenesis and progression is associated with accumulation of cell damage mediated by oxidative stress (OS), inflammation, DNA damage and other conserved mechanisms. Under the ERC Advanced Investigator Award REDOX, we developed a portfolio of advance reporter mouse models in which these types of stress can be monitored non-invasively, in real time and at single-cell resolution across all organs, tissues, and cell types. In this Proof of Concept grant, NEW-AGE, we have interrogated whether these reporter models could be used as surrogate markers, and therefore as pre-clinical models, to improve the drug discovery process for diseases of old age.
In this programme, we have studied three neurological degenerative diseases - Alzheimer's, Parkinson's and Progeria. The reporter models generated in the ERC REDOX Advanced Investigator programme were crossed with representative models of Alzheimer's disease (hBACE1-KI), Progeria syndrome (LmnaG609G) and Parkinson's disease. We interrogated the activation of the reporters in a comprehensive panel of tissues by immunohistochemistry and in vivo bioluminescence in these models. Of particular significance, we observed that the stress reporters are elevated at prodromal stages in the Alzheimer's disease-DNA damage reporter model and both the Progeria-OS/inflammation and Progeria-DNA damage models. The increased reporter expression was time-dependent and in specific disease-relevant tissues. The project has therefore produced novel, proof-of-principle data indicating that these reporter systems can be used as early biomarkers of neurodegenerative disease and ageing. This exciting development will allow studies to assess whether reporter activity can be reduced by disease-modifying therapies. Therefore, these new disease-reporter models have the capacity to accelerate the development of new therapeutic interventions and reduce the costs of pre-clinical research. The work has also demonstrated that the attenuation of stress reporters can potentially be used as in vivo biomarkers of drug efficacy in clinical trials.